Organisation paid for research Program year 2025 Source: CMS Open Payments

Research Integrity

Neither a doctor nor a teaching hospital

Research payments

$1,242,277

228 payments

Through program year 2025, Research Integrity is reported as receiving $1,242,277 in research payments, across 228 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $533,365 172
2024 Research $620,906 3
2023 Research $4,450 2
2022 Research $21,758 2
2021 Research $4,180 6
2020 Research $15,830 18
2019 Research $41,787 25

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $1,033,440 60 payments
  2. C. R. Bard, Inc. & Subsidiaries $92,600 1 payment
  3. Boehringer Ingelheim International GmbH $50,135 150 payments
  4. Novartis Pharmaceuticals Corporation $47,716 4 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $14,328 10 payments
  6. Boehringer Ingelheim Pharma GmbH & Co.KG $3,558 2 payments
  7. Merck Sharp & Dohme Corporation $500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Obesity Long term safety in patients with CV risk $625,356 5 payments
  2. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $439,702 163 payments
  3. Purest $92,600 1 payment
  4. An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $21,278 1 payment
  5. Prospective Comparison of Combined Angiotensin Neprilysin Inhibition With Lcz696 Relative to Enalapril on Central Aortic Stiffness and Ventricular Vascular Coupling in Patients With Heart Failure and Reduced Ejection Fraction $13,348 1 payment
  6. A Randomized Double Blind Placebo Controlled Event Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post Myocardial Infarction Patients With Elevated Hscrp $12,976 1 payment
  7. Vericiguat in HFpEF $11,143 8 payments
  8. Empagliflozin and Heart failure (HFrEF) $10,089 19 payments
  9. Empagliflozin and heart failure (HFpEF) $9,416 15 payments
  10. BAY1002670 Long term Safety vs SoC $3,185 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record